Tacrolimus

Phase 3Completed

1 views this week 0 watching⚡ Active

Interest: 40/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Psoriasis

Conditions

Psoriasis

Trial Timeline

— → Nov 1, 2006

NCT ID

NCT00293930

About Tacrolimus

Tacrolimus is a phase 3 stage product being developed by Astellas Pharma for Psoriasis. The current trial status is completed. This product is registered under clinical trial identifier NCT00293930. Target conditions include Psoriasis.

What happened to similar drugs?

20 of 20 similar drugs in Psoriasis were approved

Approved (20) Terminated (3) Active (0)

✅alefacept + polyvalent pneumococcal vaccineAstellas PharmaApproved

✅alefaceptAstellas PharmaApproved

✅AlefaceptAstellas PharmaApproved

✅Ilumya Injectable ProductSun PharmaceuticalApproved

✅TildrakizumabSun PharmaceuticalApproved

✅Halobetasol Topical LotionSun PharmaceuticalApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (20)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00189761	Phase 2	Completed	—	—	Bone Marrow Transplantation
NCT00293930	Phase 3	Completed	—	Nov 1, 2006	Psoriasis
NCT00189787	Phase 2	Completed	—	Aug 1, 2005	Asthma, Bronchial
NCT00189722	Phase 2	Completed	—	Jul 1, 2005	Asthma, Bronchial
NCT03465969	Approved	Completed	Mar 20, 2018	Sep 14, 2018	Kidney Transplantation
NCT02555787	Pre-clinical	Completed	Mar 5, 2015	Sep 30, 2022	Kidney Transplantation
NCT02147938	Pre-clinical	Completed	Jul 17, 2014	May 15, 2017	Renal Transplantation
NCT02143479	Pre-clinical	Completed	Jun 18, 2014	May 3, 2017	Liver Transplantation
NCT02159651	Pre-clinical	Completed	Apr 1, 2014	Dec 23, 2019	Interstitial Pneumonia Associated With Polymyositis/Dermatomyositis
NCT02057484	Pre-clinical	Completed	Mar 3, 2014	Oct 17, 2017	Liver Transplant
NCT02377609	Pre-clinical	Terminated	Oct 1, 2013	Sep 1, 2014	Validation
NCT01745159	Approved	Completed	Sep 1, 2012	Nov 1, 2013	Moderate/Severe Atopic Dermatitis
NCT01511003	Approved	Completed	Dec 5, 2011	May 11, 2015	Rheumatoid Arthritis
NCT01316133	Approved	Terminated	Apr 19, 2011	Apr 8, 2016	Lupus Nephritis
NCT01410162	Approved	Completed	Dec 1, 2010	Dec 1, 2014	Renal Transplant
NCT02963103	Approved	Terminated	May 1, 2010	Oct 1, 2012	Kidney Transplantation
NCT01224041	Approved	Completed	Aug 1, 2009	Jun 1, 2011	Rheumatoid Arthritis
NCT01224418	Approved	Completed	May 1, 2008	Aug 1, 2009	Rheumatoid Arthritis
NCT00504348	Phase 2/3	Completed	Jul 1, 2007	Jan 1, 2011	Interstitial Pneumonitis
NCT01410747	Pre-clinical	Completed	Apr 10, 2007	Jan 31, 2020	Lupus Nephritis

Competing Products

20 competing products in Psoriasis

See all competitors

Product	Company	Stage	Hype Score
PPC-06 400 mg QD + PPC-06 400 mg BID + PPC-06 600 mg + Placebo	Dr. Reddy's Laboratories	Phase 2	32
XP23829 400 mg QD + XP 23829 800 mg QD + XP23829 400 mg BID + Placebo	Dr. Reddy's Laboratories	Phase 2	32
Ixekizumab + Placebo	Eli Lilly	Phase 2	35
VTX958 Dose A + VTX958 Dose B + VTX958 Dose C + VTX958 Dose D + Placebo	Ventyx Biosciences	Phase 2	21
LY2525623 Intravenous + LY2525623 Subcutaneous + Placebo Intravenous + Placebo Subcutaneous	Eli Lilly	Phase 2	27
Ixekizumab	Eli Lilly	Phase 3	40
80 mg Ixekizumab Dosing Regimens 1, 2, and 3 + Placebo	Eli Lilly	Phase 3	40
Placebo + Baricitinib	Eli Lilly	Phase 2	35
CT-P43 + Stelara	Celltrion	Phase 3	40
CT-P17 + EU-approved Humira	Celltrion	Phase 3	40
CT-P55 + EU-approved Cosentyx	Celltrion	Phase 3	44
AMG 139	AstraZeneca	Phase 1	29
alefacept + polyvalent pneumococcal vaccine	Astellas Pharma	Approved	43
alefacept	Astellas Pharma	Phase 2	35
Tacrolimus Cream	Astellas Pharma	Phase 3	40
alefacept	Astellas Pharma	Phase 3	40
peficitinib + Placebo	Astellas Pharma	Phase 2	35
Alefacept	Astellas Pharma	Phase 3	40
Amevive exposure	Astellas Pharma	Pre-clinical	18
alefacept + placebo	Astellas Pharma	Phase 3	40